Albireo to Report Q2 2022 Financial Results on August 15, 2022
Albireo Pharma (Nasdaq: ALBO) will host a conference call and audio webcast on August 15, 2022, at 4:30 p.m. ET to discuss its financial results for Q2 2022. The call aims to provide a business update and review of the company's developments in rare liver diseases, including its lead product, Bylvay, approved for treating progressive familial intrahepatic cholestasis (PFIC). Bylvay is also undergoing global Phase 3 trials for other rare pediatric liver diseases, showcasing the company’s commitment to innovative treatments.
- Bylvay is the first FDA-approved drug for PFIC, indicating a strong market position.
- Ongoing Phase 3 trials for Alagille syndrome and biliary atresia demonstrate pipeline expansion.
- None.
Conference call and webcast to be held at 4:30 pm ET
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 15, 2022, to provide a business update and review the company’s financial results for the quarter ended June 30, 2022.
To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10019926. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for 3 months following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What is Albireo Pharma's conference call about on August 15, 2022?
What is Bylvay and why is it significant?
When will Albireo Pharma present its financial results?
